StephenAHarrisonMD

Gastroenterology • Fort Sam Houston, TX

Physician

Join to view full profile

Dr. Harrison is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Harrison's full profile

Already have an account?

Office
3851 Roger Brooke Dr
Gastroenterology 3rd Floor Mche Mdg
Fort Sam Houston, TX 78234
Phone+1 210-916-5553

Fax+1 210-916-2601
Is this information wrong?

Education & Training

San Antonio Uniformed Services Health Education ConsortiumFellowship, Gastroenterology, 1999 - 2002
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1995 - 1998
San Antonio Uniformed Services Health Education ConsortiumInternship, Transitional Year, 1995 - 1995
University of Mississippi School of MedicineClass of 1995

Certifications & Licensure

TX State Medical License 2016 - 2025
MS State Medical License 1997 - 2024
MO State Medical License 2002 - 2017

Clinical Trials

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Start of enrollment: 2005 Aug 01
Completed
Phase 4
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC Start of enrollment: 2002 Feb 01
Completed
Phase 4
Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin Start of enrollment: 2005 Oct 01
Completed
Phase 4
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C Start of enrollment: 2007 Jul 01
Completed
Phase 2
Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis Start of enrollment: 2008 Apr 01
Completed
Phase 2
Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2007 Apr 01
Unknown status
Phase 2
Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects Start of enrollment: 2006 Jun 01
Completed
Not Applicable
The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC Start of enrollment: 2008 Dec 01
Completed
Phase 2
Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba Start of enrollment: 2008 Sep 01
Completed
Phase 4
Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition Start of enrollment: 2010 Mar 01
Withdrawn
Phase 3
Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis Start of enrollment: 2013 Jul 01
Completed
Phase 1
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis Start of enrollment: 2015 Aug 01
Completed
Phase 2
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Start of enrollment: 2015 Jun 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
Stephen A Harrison, Juan P Frias, K Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J Tillman, Ali Moulton, Brittany de Temple, Arian Za...> ;Clinical Gastroenterology and Hepatology. 2024 Mar 4
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
Layla A Abushamat, Pir Ahmad Shah, Robert H Eckel, Stephen A Harrison, Diana Barb> ;Clinical Gastroenterology and Hepatology. 2024 Feb 15
10 citations
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.
Rohit Loomba, Arun J Sanyal, Atsushi Nakajima, Brent A Neuschwander-Tetri, Zachary D Goodman, Stephen A Harrison, Eric J Lawitz, Nadege Gunn, Kento Imajo, Natarajan Ra...> ;Clinical Gastroenterology and Hepatology. 2024 Jan 1
11 citations
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
Manal F Abdelmalek, Arun J Sanyal, Atsushi Nakajima, Brent A Neuschwander-Tetri, Zachary D Goodman, Eric J Lawitz, Stephen A Harrison, Ira M Jacobson, Kento Imajo, Nad...> ;Clinical Gastroenterology and Hepatology. 2024 Jan 1
19 citations
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
Vlad Ratziu, Stephen A Harrison, Véronique Loustaud-Ratti, Christophe Bureau, Eric Lawitz, Manal Abdelmalek, Naim Alkhouri, Sven Francque, Hugo Girma, Raphaël Darteil,...> ;Journal of Hepatology. 2023 Mar 1
12 citations
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Stephen A Harrison, Carole Thang, Sébastien Bolze, Sheila Dewitt, Sophie Hallakou-Bozec, Julie Dubourg, Pierre Bedossa, Kenneth Cusi, Vlad Ratziu, Jean-Marie Grouin, D...> ;Journal of Hepatology. 2023 May 1
4 citations
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis.
Mazen Noureddin, Zachary Goodman, Dean Tai, Elaine L K Chng, Yayun Ren, Pol Boudes, Harold Shlevin, Guadalupe Garcia-Tsao, Stephen A Harrison, Naga P Chalasani> ;Alimentary Pharmacology & Therapeutics. 2023 Feb 1
8 citations
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials.
Vincent Wai-Sun Wong, Won Young Tak, George Boon Bee Goh, Pin-Nan Cheng, Eric J Lawitz, Zobair M Younossi, Raj Vuppalanchi, Ziad Younes, Naim Alkhouri, Lulu Wang, Jial...> ;Clinical Gastroenterology and Hepatology. 2023 Jan 1
17 citations
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
Stephen A Harrison, Peter J Ruane, Bradley Freilich, Guy Neff, Rashmee Patil, Cynthia Behling, Chen Hu, Reshma Shringarpure, Brittany de Temple, Erica Fong, Erik J Til...> ;JHEP Reports. 2023 Jan 1
11 citations
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.
Lung-Yi Mak, Ed Gane, Christian Schwabe, Ki Tae Yoon, Jeong Heo, Russell Scott, Jeong-Hoon Lee, Jung Il Lee, Young Oh Kweon, Martin Weltman, Stephen A Harrison, Brent ...> ;Journal of Hepatology. 2023 Apr 1
5 citations
Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in F2/F3 NASH.
Stephen A Harrison, Patrick R Mayo, Todd M Hobbs, Carlos Canizares, Erin P Foster, Caroline Zhao, Daren R Ure, Daniel J Trepanier, Jill A Greytok, Robert T Foster> ;Hepatology Communications. 2022 Dec 1
3 citations
MEFIB vs. MAST and FAST: Not a competition but useful tools.
Mazen Noureddin, Stephen A Harrison, Naim Alkhouri> ;Journal of Hepatology. 2024 Jan 1
9 citations
Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial.
Ryan W Dellinger, Holly E Holmes, Tina Hu-Seliger, Rodney W Butt, Stephen A Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente> ;Hepatology. 2023 Sep 1
1 citations
Simple diagnostic algorithm identifying at-risk nonalcoholic fatty liver disease patients needing specialty referral within the United States.
Naim Alkhouri, Pankaj Aggarwal, Phuc Le, Julia Payne, Celine Sakkal, Prido Polanco, Stephen Harrison, Mazen Noureddin> ;World Journal of Hepatology. 2022 Aug 27
28 citations
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
Christopher L Bowlus, Michael R Galambos, Richard J Aspinall, Gideon M Hirschfield, David E J Jones, Yvonne Dörffel, Stuart C Gordon, Stephen A Harrison, Andreas E Kre...> ;Journal of Hepatology. 2022 Aug 1
29 citations
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Stephen A Harrison, Manal F Abdelmalek, Guy Neff, Nadege Gunn, Cynthia D Guy, Naim Alkhouri, Mustafa R Bashir, Bradley Freilich, Anita Kohli, Arun Khazanchi, Muhammad ...> ;The Lancet. Gastroenterology & Hepatology. 2022 Jul 1
57 citations
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
Elizabeth M Brunt, Andrew D Clouston, Zachary Goodman, Cynthia Guy, David E Kleiner, Carolin Lackner, Dina G Tiniakos, Aileen Wee, Matthew Yeh, Wei Qiang Leow, Elaine ...> ;Journal of Hepatology. 2022 May 1
44 citations
Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.
Rohit Loomba, Vlad Ratziu, Stephen A. Harrison, Stefanie C. McFarlane, Nobuharu Tamaki, Manal F. Abdelmalek, Mary E. Rinella, Quentin M. Anstee, Zobair M. Younossi, Ar...> ;Gastroenterology. 2021 Nov 22
59 citations
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
Mazen Noureddin, Emily Truong, Jeffrey Gornbein, Rola Saouaf, Maha Guindi, Tsuyoshi Todo, Nabil Noureddin, Ju Dong Yang, Stephen A. Harrison, Naim Alkhouri> ;Journal of Hepatology. 2021 Nov 16
54 citations
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
Mary E. Rinella, Jean-François Dufour, Quentin M. Anstee, Zachary Goodman, Zobair M. Younossi, Stephen A. Harrison, Rohit Loomba, Arun J. Sanyal, Martin Bonacci, A. Tr...> ;Journal of Hepatology. 2021 Nov 15
181 citations
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
Fasiha Kanwal, Leon A. Adams, Kim Pfotenhauer, Vincent Wai-Sun Wong, Eugene E. Wright, Manal F. Abdelmalek, Stephen A. Harrison, Rohit Loomba, Christos S. Mantzoros, E...> ;Gastroenterology. 2021 Nov 1
22 citations
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo...
Kenneth Cusi, Naim Alkhouri, Stephen A. Harrison, Pascale Fouqueray, David E. Moller, Sophie Hallakou-Bozec, Sébastien Bolze, Jean-Marie Grouin, S. Megnien, Julie Dubo...> ;The Lancet. Gastroenterology & Hepatology. 2021 Nov 1
86 citations
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
Rohit Loomba, Rizwana Mohseni, K. Jean Lucas, Julio A. Gutierrez, Robert G. Perry, James F. Trotter, Robert S. Rahimi, Stephen A. Harrison, Veeral Ajmera, Jeffrey D. W...> ;Gastroenterology. 2021 Nov 1
7 citations
Improved Ultrasound Attenuation Measurement Method for the Non-invasive Evaluation of Hepatic Steatosis Using FibroScan.
Stephane Audiere, Aymeric Labourdette, Véronique Miette, Céline Fournier, Redouane Ternifi, Salem Boussida, Philippe Pouletaut, Fabrice Charleux, Sabine F. Bensamoun, ...> ;Ultrasound in Medicine & Biology. 2021 Nov 1
Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
Michael Pavlides, Ferenc E. Mózes, Stephen A. Harrison> ;Gut. 2021 Oct 27
Join now to see all

Journal Articles

The Lancet Child & Adolescent Health
Arun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet

Press Mentions

Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 ‘ALTITUDE-NASH’ Liver Function TrialSeptember 12th, 2022
SGLT1/2 Inhibitor Shows Early Promise in NASHJune 22nd, 2022
AXA1125 Safe, Well Tolerated up to 16 Weeks in Patients with NAFLDAugust 17th, 2021
Join now to see all

Hospital Affiliations

Brooke Army Medical CenterFort Sam Houston, Texas
Wilford Hall Medical CenterRandolph AFB, Texas

StephenAHarrisonMD

Dr. Harrison is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.